Literature DB >> 22584804

The role of a mineralocorticoid receptor gene functional polymorphism in the symptom dimensions of persistent ADHD.

Gustavo Lucena Kortmann1, Verônica Contini, Guilherme Pinto Bertuzzi, Nina Roth Mota, Diego Luiz Rovaris, Vanessa Rodrigues Paixão-Côrtes, Leandro Leal de Lima, Eugenio Horacio Grevet, Carlos Alberto Iglesias Salgado, Eduardo Schneider Vitola, Luis Augusto Rohde, Paulo Belmonte-de-Abreu, Claiton Henrique Dotto Bau.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) affects approximately 5 % of school-aged children and 2.5 % of adults. Genetic studies in ADHD have pointed to genes in different neurobiological systems, with relatively small individual effects. The mineralocorticoid receptor is the main receptor involved in the initial triggering of stress response. Therefore, its encoding gene (NR3C2) is a candidate for psychiatric disorder studies, including ADHD, and behavioral phenotypes. There is evidence that the Val allele of the MRI180V polymorphism (rs5522) increases the risk of depression, attention and cognitive deficits. We investigated the possible role of the mineralocorticoid receptor gene in the symptom dimensions and susceptibility to persistent ADHD. We compared genotype and allele frequencies in 478 adult patients with ADHD and 597 controls and symptom dimensions in 449 patients and 132 controls. Diagnoses were based on the DSM-IV criteria. ADHD symptom dimensions were investigated with SNAP-IV for ADHD severity and Barkley scales for severity and impairment. Carriers of the Val allele presented higher inattention, hyperactivity/impulsivity and impairment scores, while genotype and allele frequencies did not differ between patients and controls. These results are consistent with a possible link between genetic variations in the HPA axis and inattention and hyperactivity measures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584804     DOI: 10.1007/s00406-012-0321-z

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  60 in total

Review 1.  [Emotional dysfunctions in attention deficit hyperactivity disorder].

Authors:  D Purper-Ouakil; N Franc
Journal:  Arch Pediatr       Date:  2011-04-14       Impact factor: 1.180

2.  Human mineralocorticoid receptor (MR) gene haplotypes modulate MR expression and transactivation: implication for the stress response.

Authors:  Nienke van Leeuwen; Silja Bellingrath; E Ronald de Kloet; Frans G Zitman; Roel H DeRijk; Brigitte M Kudielka; Stefan Wüst
Journal:  Psychoneuroendocrinology       Date:  2010-11-20       Impact factor: 4.905

3.  Self-reported ADHD and adjustment in college: cross-sectional and longitudinal findings.

Authors:  Stacey L Blase; Adrianne N Gilbert; Arthur D Anastopoulos; E Jane Costello; Rick H Hoyle; H Scott Swartzwelder; David L Rabiner
Journal:  J Atten Disord       Date:  2009-05-27       Impact factor: 3.256

4.  Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism.

Authors:  Keiko Arai; Yoshiko Nakagomi; Mitsue Iketani; Yoshie Shimura; Shin Amemiya; Kenji Ohyama; Tamotsu Shibasaki
Journal:  Hum Genet       Date:  2002-10-25       Impact factor: 4.132

5.  Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation.

Authors:  J M Reul; E R de Kloet
Journal:  Endocrinology       Date:  1985-12       Impact factor: 4.736

6.  Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.

Authors:  Christian Otte; Steffen Moritz; Alexander Yassouridis; Maike Koop; Ana Maria Madrischewski; Klaus Wiedemann; Michael Kellner
Journal:  Neuropsychopharmacology       Date:  2006-10-11       Impact factor: 7.853

Review 7.  Brain corticosteroid receptor balance in health and disease.

Authors:  E R De Kloet; E Vreugdenhil; M S Oitzl; M Joëls
Journal:  Endocr Rev       Date:  1998-06       Impact factor: 19.871

8.  Child psychiatric sequelae of maternal war stress.

Authors:  A Meijer
Journal:  Acta Psychiatr Scand       Date:  1985-12       Impact factor: 6.392

9.  Attention-deficit hyperactivity disorder and the stress response.

Authors:  J A King; R A Barkley; S Barrett
Journal:  Biol Psychiatry       Date:  1998-07-01       Impact factor: 13.382

Review 10.  Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis.

Authors:  Viktória Simon; Pál Czobor; Sára Bálint; Agnes Mészáros; István Bitter
Journal:  Br J Psychiatry       Date:  2009-03       Impact factor: 9.319

View more
  4 in total

1.  Risk genes, metabolic syndrome and eye tracking deficits in psychiatric diseases.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04       Impact factor: 5.270

2.  MR and GR functional SNPs may modulate tobacco smoking susceptibility.

Authors:  Diego L Rovaris; Nina R Mota; Lucas A de Azeredo; Renata B Cupertino; Guilherme P Bertuzzi; Evelise R Polina; Verônica Contini; Gustavo L Kortmann; Eduardo S Vitola; Eugenio H Grevet; Rodrigo Grassi-Oliveira; Sidia M Callegari-Jacques; Claiton H D Bau
Journal:  J Neural Transm (Vienna)       Date:  2013-03-31       Impact factor: 3.575

3.  Further evidence for the association between a polymorphism in the promoter region of SLC6A3/DAT1 and ADHD: findings from a sample of adults.

Authors:  Lucas A de Azeredo; Diego L Rovaris; Nina R Mota; Evelise R Polina; Francine Z Marques; Verônica Contini; Eduardo S Vitola; Paulo Belmonte-de-Abreu; Luis A Rohde; Eugenio H Grevet; Claiton H D Bau
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-02-01       Impact factor: 5.270

Review 4.  Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies.

Authors:  C Bonvicini; S V Faraone; C Scassellati
Journal:  Mol Psychiatry       Date:  2016-05-24       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.